Item 5. Other Information
Item 5. Other Information
On May 18, 2020 and May 19, 2020, pursuant
to the Nevada Revised Statutes and the Bylaws of the Company, the Board of Directors of the Company and the stockholders holding
a majority of 50.3% of the Company’s outstanding voting outstanding capital stock, respectively, approved the filing of an
amendment to the Articles of Incorporation of the Company to increase the authorized amount of common stock from 750,000,000 to
1,500,000,000, without changing the par value of the common stock or authorized number and par value of “blank check”
Preferred Stock. On June 2, 2020, the Company filed a Definitive 14C with the SEC regarding the corporate action. On June 24, 2020,
the Company filed a Certificate of Amendment to the Company’s Articles of Incorporation with the Secretary of State of Nevada
to effectuate the corporate action on June 24, 2020.
37
Item
6 . Exhibits
Exhibit No:
Description:
31.1*
Rule 13(a)-14(a)/15(d)-14(a) Certification of Principal Executive Officer
31.2*
Rule 13(a)-14(a)/15(d)-14(a) Certification of Principal Financial and Accounting Officer
32.1*
Section 1350 Certification of Principal Executive Officer
32.2*
Section 1350 Certification of Principal Financial and Accounting Officer
101.INS **
XBRL Instance Document
101.SCH**
XBRL Taxonomy Extension Schema Document
101.CAL**
XBRL Taxonomy Extension Calculation Linkbase Document
101.LAB**
XBRL Taxonomy Extension Labels Linkbase Document
101.DEF**
XBRL Taxonomy Extension Definition Linkbase Document
101.PRE**
XBRL Taxonomy Extension Presentation Linkbase Document
*
Filed herewith.
**
Pursuant to Rule 406T of Regulation S-T, these interactive data files are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934 and otherwise are not subject to liability under those sections.
All of the Exhibits
are available from the SEC’s website at www.sec.gov. In addition, the Company will furnish a copy of any Exhibit upon payment
of a fee (based on the estimated actual cost which shall be determined at the time of the request) together with a request addressed
to Albert Mitrani, Organicell Regenerative Medicine Inc., 4045 Sheridan Ave, Suite 239, Miami, FL 33140.
38
SIGNATURES
Pursuant to the requirements of Section
13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
ORGANICELL REGENERATIVE MEDICINE, INC.
By:
/s/ ALBERT MITRANI
Albert Mitrani
Chief Executive Officer
(Principal Executive Officer)
By:
December 17, 2020
/ s/ IAN T. BOTHWELL
Ian T. Bothwell
Chief Financial Officer
(Principal Financial and Accounting Officer)
December 17, 2020
39
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the original document is authoritative for anything you rely on.